A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway.

Oncotarget 2015 Dec;6(39):41736-49

Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, UK.

Our identification of dysregulation of the AKT pathway in ovarian cancer as a platinum resistance specific event led to a comprehensive analysis of in vitro, in vivo and clinical behaviour of the AKT inhibitor GSK2141795. Proteomic biomarker signatures correlating with effects of GSK2141795 were developed using in vitro and in vivo models, well characterised for related molecular, phenotypic and imaging endpoints. Signatures were validated in temporally paired biopsies from patients treated with GSK2141795 in a clinical study. GSK2141795 caused growth-arrest as single agent in vitro, enhanced cisplatin-induced apoptosis in vitro and reduced tumour volume in combination with platinum in vivo. GSK2141795 treatment in vitro and in vivo resulted in ~50-90% decrease in phospho-PRAS40 and 20-80% decrease in fluoro-deoxyglucose (FDG) uptake. Proteomic analysis of GSK2141795 in vitro and in vivo identified a signature of pathway inhibition including changes in AKT and p38 phosphorylation and total Bim, IGF1R, AR and YB1 levels. In patient biopsies, prior to treatment with GSK2141795 in a phase 1 clinical trial, this signature was predictive of post-treatment changes in the response marker CA125. Development of this signature represents an opportunity to demonstrate the clinical importance of AKT inhibition for re-sensitisation of platinum resistant ovarian cancer to platinum.

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.6153DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747185PMC
December 2015
94 Reads

Publication Analysis

Top Keywords

vitro vivo
20
ovarian cancer
8
akt inhibition
8
vivo clinical
8
cancer platinum
8
gsk2141795
7
vitro
7
vivo
6
clinical
5
akt
5
gsk2141795 caused
4
gsk2141795 phase
4
clinical study
4
study gsk2141795
4
treatment gsk2141795
4
growth-arrest single
4
vitro enhanced
4
patient biopsies
4
enhanced cisplatin-induced
4
levels patient
4

Similar Publications